Report initial Phase 1 data for OMS906, the MASP-3 inhibitor
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial data are expected next quarter from the Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics, safety and tolerability of OMS906”
What we found
Evidence strength A What the grades mean
Later 10-Q filings state preliminary Phase 1 data for OMS906 were reported in June 2021, within the next-quarter window ending June 30, 2021.
-
A Omeros Corp. 8-K filed 2021-08-09
“oOmeros announced preliminary results from the Phase 1 clinical trial evaluating the pharmacokinetics/pharmacodynamics (PK/PD) and safety of OMS906 in healthy subjects.” ✓ confirmed on the page
-
A Omeros Corp. 10-Q filed 2021-08-09
“reported preliminary data from the Phase 1 trial in June 2021” ✓ confirmed on the page
-
A Omeros Corp. 10-Q filed 2021-11-09
“reported preliminary data from the Phase 1 trial in June 2021” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Initial Phase 1 data for OMS906
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Omeros Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OMER-024891 · Corrections policy